Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Apr;12(4):339-45.
doi: 10.1016/S1474-4422(13)70037-1. Epub 2013 Feb 27.

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

UKMND-LiCALS Study Group; K E Morrison, S Dhariwal, R Hornabrook, L Savage, D J Burn, T K Khoo, J Kelly, C L Murphy, A Al-Chalabi, A Dougherty, P N Leigh, L Wijesekera, M Thornhill, C M Ellis, K O'Hanlon, J Panicker, L Pate, P Ray, L Wyatt, C A Young, L Copeland, J Ealing, H Hamdalla, I Leroi, C Murphy, F O'Keeffe, E Oughton, L Partington, P Paterson, D Rog, A Sathish, D Sexton, J Smith, H Vanek, S Dodds, T L Williams, I N Steen, J Clarke, C Eziefula, R Howard, R Orrell, K Sidle, R Sylvester, W Barrett, C Merritt, K Talbot, M R Turner, C Whatley, C Williams, J Williams, C Cosby, C O Hanemann, I Iman, C Philips, L Timings, S E Crawford, C Hewamadduma, R Hibberd, H Hollinger, C McDermott, G Mils, M Rafiq, P J Shaw, A Taylor, E Waines, T Walsh, R Addison-Jones, J Birt, M Hare, T Majid
Collaborators
Clinical Trial

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

UKMND-LiCALS Study Group et al. Lancet Neurol. 2013 Apr.

Erratum in

  • Lancet Neurol. 2013 Sep;12(9):846

Abstract

Background: Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival. We aimed to assess whether lithium improves survival in patients with ALS.

Methods: The lithium carbonate in amyotrophic lateral sclerosis (LiCALS) trial is a randomised, double-blind, placebo-controlled trial of oral lithium taken daily for 18 months in patients with ALS. Patients aged at least 18 years who had ALS according to the revised El Escorial criteria, had disease duration between 6 and 36 months, and were taking riluzole were recruited from ten centres in the UK. Patients were randomly assigned (1:1) to receive either lithium or matched placebo tablets. Randomisation was via an online system done at the level of the individual by block randomisation with randomly varying block sizes, stratified by study centre and site of disease onset (limb or bulbar). All patients and assessing study personnel were masked to treatment assignment. The primary endpoint was the rate of survival at 18 months and was analysed by intention to treat. This study is registered with Eudract, number 2008-006891-31.

Findings: Between May 26, 2009, and Nov 10, 2011, 243 patients were screened, 214 of whom were randomly assigned to receive lithium (107 patients) or placebo (107 patients). Two patients discontinued treatment and one died before the target therapeutic lithium concentration could be achieved. 63 (59%) of 107 patients in the placebo group and 54 (50%) of 107 patients in the lithium group were alive at 18 months. The survival functions did not differ significantly between groups (Mantel-Cox log-rank χ(2) on 1 df=1·64; p=0·20). After adjusting for study centre and site of onset using logistic regression, the relative odds of survival at 18 months (lithium vs placebo) was 0·71 (95% CI 0·40-1·24). 56 patients in the placebo group and 61 in the lithium group had at least one serious adverse event.

Interpretation: We found no evidence of benefit of lithium on survival in patients with ALS, but nor were there safety concerns, which had been identified in previous studies with less conventional designs. This finding emphasises the importance of pursuing adequately powered trials with clear endpoints when testing new treatments.

Funding: The Motor Neurone Disease Association of Great Britain and Northern Ireland.

PubMed Disclaimer

Figures

Figure
Figure
Trial profile
See this image and copyright information in PMC

Comment in

  • The final chapter of the ALS lithium saga.
    Chiò A, Mora G. Chiò A, et al. Lancet Neurol. 2013 Apr;12(4):324-5. doi: 10.1016/S1474-4422(13)70040-1. Epub 2013 Feb 27. Lancet Neurol. 2013. PMID: 23453346 No abstract available.

References

    1. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–1431. - PubMed
    1. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA. 1999;96:8745–8750. - PMC - PubMed
    1. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem. 2002;80:589–597. - PubMed
    1. Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang DM. Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience. 2003;117:55–61. - PubMed
    1. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology. 2002;43:1173–1179. - PubMed

Publication types